Pharma-Bio Serv, Inc. (PBSV)
OTCMKTS
· Delayed Price · Currency is USD
0.490
-0.100 (-16.95%)
At close: Feb 27, 2026
Pharma-Bio Serv Income Statement
Financials in millions USD. Fiscal year is November - October.
Millions USD. Fiscal year is Nov - Oct.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | 2020 - 2016 |
| Revenue | 9 | 9.51 | 16.98 | 19.4 | 20.12 | Upgrade
|
| Revenue Growth (YoY) | -5.34% | -43.99% | -12.48% | -3.56% | -6.72% | Upgrade
|
| Cost of Revenue | 6.09 | 6.99 | 11.91 | 14.52 | 14.76 | Upgrade
|
| Gross Profit | 2.91 | 2.52 | 5.07 | 4.88 | 5.36 | Upgrade
|
| Selling, General & Admin | 3.55 | 3.8 | 3.95 | 3.71 | 4.01 | Upgrade
|
| Operating Expenses | 3.55 | 3.8 | 3.95 | 3.71 | 9.21 | Upgrade
|
| Operating Income | -0.64 | -1.29 | 1.12 | 1.17 | -3.85 | Upgrade
|
| Interest & Investment Income | 0.64 | 0.53 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.1 | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | 0.57 | 0.01 | 0.02 | Upgrade
|
| EBT Excluding Unusual Items | -0.09 | -0.76 | 1.69 | 1.19 | -3.83 | Upgrade
|
| Other Unusual Items | - | - | - | - | 1.96 | Upgrade
|
| Pretax Income | -0.09 | -0.76 | 1.69 | 1.19 | -1.88 | Upgrade
|
| Income Tax Expense | 0.01 | 0.02 | 0.38 | 0.18 | 0.21 | Upgrade
|
| Earnings From Continuing Operations | -0.1 | -0.78 | 1.31 | 1.01 | -2.09 | Upgrade
|
| Net Income | -0.1 | -0.78 | 1.31 | 1.01 | -2.09 | Upgrade
|
| Net Income to Common | -0.1 | -0.78 | 1.31 | 1.01 | -2.09 | Upgrade
|
| Net Income Growth | - | - | 30.15% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 23 | 23 | 23 | 23 | 23 | Upgrade
|
| Shares Outstanding (Diluted) | 23 | 23 | 23 | 23 | 23 | Upgrade
|
| Shares Change (YoY) | -0.07% | -0.10% | -0.15% | -0.56% | 0.53% | Upgrade
|
| EPS (Basic) | -0.00 | -0.03 | 0.06 | 0.04 | -0.09 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.03 | 0.06 | 0.04 | -0.09 | Upgrade
|
| EPS Growth | - | - | 30.25% | - | - | Upgrade
|
| Free Cash Flow | -0.22 | -0.73 | 1.88 | 0.57 | 0.79 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.03 | 0.08 | 0.03 | 0.03 | Upgrade
|
| Gross Margin | 32.33% | 26.46% | 29.84% | 25.16% | 26.65% | Upgrade
|
| Operating Margin | -7.08% | -13.54% | 6.58% | 6.06% | -19.16% | Upgrade
|
| Profit Margin | -1.12% | -8.18% | 7.72% | 5.19% | -10.39% | Upgrade
|
| Free Cash Flow Margin | -2.46% | -7.64% | 11.10% | 2.96% | 3.95% | Upgrade
|
| EBITDA | -0.58 | -1.26 | 1.17 | 1.23 | -3.78 | Upgrade
|
| EBITDA Margin | -6.42% | -13.30% | 6.87% | 6.32% | -18.80% | Upgrade
|
| D&A For EBITDA | 0.06 | 0.02 | 0.05 | 0.05 | 0.07 | Upgrade
|
| EBIT | -0.64 | -1.29 | 1.12 | 1.17 | -3.85 | Upgrade
|
| EBIT Margin | -7.08% | -13.54% | 6.58% | 6.06% | -19.16% | Upgrade
|
| Effective Tax Rate | - | - | 22.36% | 15.29% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.